TuHURA Biosciences (HURA) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
9 Jul, 2026Executive summary
Annual meeting scheduled for August 18, 2026, to be held virtually for shareholder participation.
Shareholders are encouraged to review proxy materials online and can request paper or email copies at no charge.
Voting matters and shareholder proposals
Election of six directors to serve until the 2027 annual meeting or until successors are qualified.
Approval sought for issuance of 1,878,287 shares of common stock under a Fee Letter with Parkview Holdings One LLC.
Advisory vote on executive compensation and on the frequency of future say-on-pay votes.
Ratification of Cherry Bekaert LLP as independent auditor for fiscal year ending December 31, 2026.
Provision for other business to be transacted as may properly come before the meeting.
Board of directors and corporate governance
Six nominees listed for director positions: James A Bianco, James Manuso, Alan List, George Ng, Robert Hoffman, and Craig Tendler.
Latest events from TuHURA Biosciences
- Q2 2026 net loss was $9.2M; cash at $1.0M; $50M credit facility extends runway into 2028.HURA
Q2 2026 - Advancing phase III immunotherapy for Merkel cell carcinoma with FDA SPA and novel AML programs.HURA
Canaccord Genuity's 46th Annual Growth Conference - Advancing late-stage immuno-oncology assets to overcome resistance in cancer treatment.HURA
Corporate presentation - Shareholders to vote on director elections, major share issuance, and executive pay; board recommends approval.HURA
Proxy filing - Shareholders will vote on director elections, share issuance, compensation, and auditor ratification.HURA
Proxy filing - Clinical-stage immuno-oncology firm expands pipeline via merger, but faces ongoing financial and execution risks.HURA
Registration filing - Diversified immuno-oncology pipeline advances amid ongoing losses and high funding needs.HURA
Registration filing - Up to $250M in securities registered, including $50M ATM, to fund oncology pipeline and operations.HURA
Registration filing - Merger completed, cash burn persists, and urgent funding needs threaten going concern.HURA
Q3 2024